11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

A record year for Leukaemia UK London Marathon runners

21 September 2022

A record year for Leukaemia UK London Marathon runners

62 runners put their best feet forward for Leukaemia UK A record 62 runners are taking part in this year’s London marathon to help fund vital research into leukaemia diagnosis,…

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

18 October 2021

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

9 November 2017

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

We are a leading charity making a difference to families affected by leukaemia, lymphoma, myeloma and other blood cancers.

Leukaemia UK appoints new CEO

27 August 2020

Leukaemia UK appoints new CEO

The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, starting her role on 9th September 2020.